ANXA2 and esophageal squamous cell carcinoma: Our current study not only illustrates that the SRC-ANXA2-MYC-HIF1A-VEGF signaling pathway contributes to the progression of ESCC but also provides novel molecular targets and therapeutic strategies for the treatment of ESCC.